Efficacy of inactivated vaccine containing cyto-hemagglutinin against epidemic hemorrhagic fever in rabbits.
Using the Z-10 strain of epidemic hemorrhagic fever virus (EHFV) as seed, and the primary cell of Meriones unguiculatus kidney tissue as incubation cell, a propiolactone inactivated epidemic hemorrhagic fever (EHF) vaccine was prepared, according to a similar procedure required for the production of biological products such as the Japanese B encephalitis vaccine. Besides the EHFV antigen detected by ELISA or reversed passive hemagglutination test (RPHA) as were used for the formalin inactivated vaccine, higher titres (1:128-1:1024) of EHFV hemagglutinin antigen was also detected in this EHFV vaccine. Immunization with twice intramuscular injection of this vaccine produced high titred (1:20-1:160) neutralizing antibody and low titred (1:10-1:20) hemagglutination antibody, in addition to the immunofluorescence (IF) and reversed passive hemagglutination inhibition (RPHI) antibodies. These results indicated an apparent difference in the immunogenicity between the beta-propiolactone and formalin inactivated EHF vaccines. With the approval of the Ministry of Health, human test is now underway in this laboratory.
Zhu
Z Y
ZY
Tang
H Y
HY
Li
Y J
YJ
Weng
J Q
JQ
Fu
G M
GM
D000818:Animals; D005260:Female; D006476:Orthohantavirus / Q000276:immunology*; D006389:Hemagglutinins, Viral / Q000276:immunology*; D006480:Hemorrhagic Fever with Renal Syndrome / Q000517:prevention & control*; D008297:Male; D011817:Rabbits; D015164:Vaccines, Inactivated; D014765:Viral Vaccines
D006389:Hemagglutinins, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines